Takeda to Withdraw Oncology Drug Exkivity from U.S. Market

Takeda is voluntarily withdrawing Exkivity (mobocertinib) from the U.S. market because a phase 3 confirmatory study did not meet its primary endpoint. Exkivity was granted accelerated approval in September 2021 to treat adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.